Open-access status Open access under the Creative Commons CC BY 4.0 license
More controlled human research is needed before conclusions can be drawn about long-term safety or downstream health and performance outcomes
The first category consists of prodrugs containing a GSH or GSH-like structure for which a -elimination reaction, catalyzed by GST, releases a cytotoxic compound
This data offers meaningful proof that a structured, clinically integrated GLP-1 strategy can deliver millions in real savings without compromising access or member outcomes.* Employer health strategies have traditionally centered on condition-specific programs to manage diseases like obesity, diabetes, and cardiovascular conditions individually, which has led to employers managing multiple point solutions simultaneously, often with low coordination, engagement, and return on investment
Research-grade retatrutide is available for purchase by qualified researchers in Canada
Obesity medications approved by the FDA for long-term use include orlistat (Xenical, Alli), phentermine-topiramate ER (Qsymia), naltrexone-bupropion ER (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (Foundayo)